From: Combined amino acid PET-MRI for identifying recurrence in post-treatment gliomas: together we grow
No | Age | Location | Histology | Grade | Molecular subtype | Surgical Details immediate post op imaging not done to assess extent of resection | Chemo/Radiotherapy | Interval between Post treatment completion and PET/MRI | Duration of follow up Post PET/MRI |
---|---|---|---|---|---|---|---|---|---|
1 | 52/M | Right parietal | GBM | IV | IDH wild-type | 2009: Partial resection 2009 2017: Gross Total excision of recurrence | 2009: EBRT-56 Gy in 28 # with concurrent TMZ 2017: IMRT 60 Gy in 30 #, with concurrent and adjuvant TMZ completed in 2018) | 12 | 12 |
2 | 44/M | Right posterior frontal | AA | III | IDH mutant, loss of p53 | 2012:Gross total excision 2017: Re-exploration and decompression 2017 | 2012: 56 Gy in 28 # with concurrent TMZ 2017: TMZ completed in 2018 | 12 | 13 |
3 | 42/M | Right insula | AA | III | IDH mutant | 2017: Subtotal resection | 2017: EBRT 55 Gy in 31 cycles Concurrent and Adjuvant TMZ till 2018 | 12 | 13 |
4 | 71/M | Left frontal | GBM | IV | IDH wildtype | 2019: Gross total excision | Defaulted treatment | Â | 1 |
5 | 40/F | Right Parietal | AA | III | IDH mutant | 2013: Partial resection | 2013: EBRT 60 Gy in 30 # with concurrent TMZ | 72 | 3 |
6 | 32/F | Left frontal | AA | III | IDH mutant | 2009: Partial resection 2013: Subtotal excision 2018: Decompression with Gross total excision | 2014: EBRT 50 Gy 28 # with concurrent TMZ 2018: EBRT 30Gy in 15 cycles with concurrent TMZ | 12 | 1 |
7 | 44/M | Right frontal | Astrocytoma | II | IDH mutant | Gross total resection 2018 | Defaulted treatment | 12 | 12 |
8 | 39/M | Right frontal | AODG | III | FISH not done | 2012: Subtotal excision | 2012: EBRT 60 Gy 30 # with concurrent TMZ | 84 | 11 |
9 | 45/M | Right temporoparietal | GBM | IV | IDH wildtype | 2018: Gross Total excision | 2018: IMRT with concurrent and adjuvant TMZ (last 2018) | 12 | 4 |
10 | 22/M | Right parietooccipital | GBM | IV | IDH wildtype | 2013: Gross Total excision | 2013: EBRT 46 Gy 25 #, 10 Gy 15 # with concurrent TMZ | 72 | 3 |
11 | 30/M | Left temporal | AA | III | IDH mutant | 2018: Gross Total excision | 2019: EBRT 45 Gy 25 # booster 14.4 Gy 8 # with concurrent TMZ | 24 | 6 |
12 | 39/M | Left inferior frontal | AA | III | IDH wildtype | 2018: Gross Total excision | 2018-2019 EBRT 60 Gy 30 # with concurrent TMZ | 1 | 12 |
13 | 34/F | Right frontal | AODG | III | IDH mutant | 2018: Decompression | 2019: EBRT 59.4Gy in 33 # with concurrent TMZ | 12 | 5 |
14 | 16/M | Left thalamus | Midline glioma | IV | H3K27 mutant | 2019: Partial excision and decompression | 2019: TMZ followed by EBRT: 49.5 Gy 33 # | 1 | 9 |
15 | 29/M | Right parietal | GBM | IV | IDH wildtype | 2017: Decompression 2018: Not operable | 2017: EBRT 60Gy in 30 # with concurrent TMZ 2018: TMZ | 18 | 4 |
16 | 42/F | Left frontal | AA | III | IDH mutant | 2016: Gross Total excision | 2016: EBRT 60 Gy 30 # with concurrent TMZ | 32 | 3 |
17 | 51/F | Left temporal | GBM | IV | IDH wildtype | 2018: Gross Total excision | 2018: 2016: EBRT 60 Gy 30 # with concurrent TMZ | 2 | 10 |
18 | 29/F | Right parietal | GBM | IV | NOS(R132H negative) | 2018: Gross Total excision | 2019: IMRT 59.5 Gy 33 # with concurrent TMZ | 1 | 7 |
19 | 40/M | Left temporal | GBM | IV | NOS(R132H negative) | 2018: Near total excision 2019: Gross Total excision | 2018: EBRT 54.4 Gy 33 # with concurrent TMZ | 13 | 1 |
20 | 8/F | Right frontoparietal | High grade glioma | IV | IDH wildtype | 2018: Gross Total resection | 2018: IMRT RT 60Gy 33 # with concurrent TMZ | 20 | 3 |
21 | 16/M | Right Frontal | Spindle cell Sarcoma | III | NA | 2016: Near total excision | 2018: EBRT 54.4 Gy 33 # with concurrent TMZ | Â | Â |
22 | 29/F | Left frontal | AA | III | IDH wildtype | 2017: Gross Total excision | 2017: EBRT 60Gy 33 # with concurrent TMZ | 24 | 10 |
23 | 44/M | Right frontal | AA | III | IDH mutant | 2016: Gross total excision | 2016: EBRT 60Gy 30 # with concurrent TMZ | 33 | 9 |
24 | 45/F | Right temporoparietal | AODG; Final-Anaplastic ependymoma | III | IDH wildtype, L1CAM positive | 2017: Gross total excision | 2017: EBRT 60Gy 30 # with concurrent TMZ | 24 | 1 |
25 | 32/F | Left temporoparietal | AODG | III | IDH mutant | 2018: Near Total excision | 2018 EBRT 60Gy 30 # with concurrent TMZ | 12 | 3 |
26 | 35/F | Left parietal | AODG | III | R132H negative | 2017: Decompression with near total excision | 2018: EBRT 60Gy 30 # with concurrent and adjuvant TMZ | 8 | 7 |
27 | 31/M | Left frontoinsular | AODG | III | IDH mutant | 2019: Subtotal excision n | 2019: EBRT 60Gy 30 # with concurrent and adjuvant TMZ (on going) | 1 | 3 |
28 | 44/M | Right frontal and corpus callosum | ODG | II | NA | 2014: Subtotal excision | 2014: Incomplete treatment EBRT 10 # 2019: 6 cycles of TMZ | 60 | 8 |
29 | 48/M | Right parietooccipital | AA | III | IDH mutant | 2017: Near Total excision | 2017: EBRT 60Gy 30 # with concurrent TMZ | 29 | 7 |
30 | 28/M | Left temporal | GBM | IV | IDH wildtype | 2015: Subtotal excision | 2016: EBRT 60Gy 30 # with concurrent TMZ | 59 | 1 |
31 | 59/M | Right temporal | GBM | IV | IDH wildtype | 2019: Gross total excision 2020: Recurrence- Gross total resection | 2019: EBRT 60Gy 30 # with concurrent TMZ 2020: Adjuvant TMZ | 4 | 1 |
32 | 47/M | Left temporoparietal | AODG | III | IDH mutant | 2015: Gross total excision | 2016: EBRT 60Gy 30 # with concurrent TMZ | 48 | 6 |
33 | 30/M | Corpus callosum | GBM | IV | IDH wildtype | 2016: Partial resection | 2016:EBRT 43 Gy in 23 # with concurrent TMZ | 40 | 1 |
34 | 31/M | Bifrontal | AODG | III | IDH mutant | 2018: Near total excision | 2019: EBRT 60 Gy in 30 #, with concurrent TMZ | 11 | 5 |
35 | 35/M | Right parietal | ODG | II | IDH mutant | 2016: Gross Total excision | 2016: EBRT 55.8 Gy in 30# no chemotherapy | 40 | 4 |
36 | 40/M | Right frontal | AA | III | IDH mutant | 2019: Gross Total excision | 2019: EBRT 60 Gy in 30 #, with concurrent TMZ | 7 | 7 |
37 | 43/F | Right parietal | AODG | III | NA | 2013: Subtotal excision | 2013; EBRT 60 Gy in 30 #, NO chemotherapy received, lost to follow-up for 6 years | 78 | 5 |
38 | 68/M | Left frontal | GBM | IV | IDH wildtype | 2019: Gross total excision | 2020: EBRT 60 Gy in 30 #, with concurrent TMZ | 1 | 4 |
39 | 32/F | Right frontal | AODG | III | IDHR132H neg | 2018: Gross Total excision | 2018: EBRT 60 Gy in 33 cycles#, with concurrent TMZ | 15 | 4 |
40 | 51/F | Right frontal | AODG | III | IDH mutant | 2018: Gross Total excision | 2018: EBRT 60 Gy in 33 cycles#, with concurrent TMZ | 22 | 4 |
41 | 36/M | Right frontal | AA | III | IDH mutant | 2018: Gross Total excision | 2018: EBRT 60 Gy in 30 cycles#, with concurrent TMZ | 17 | 13 |
42 | 57/M | Right frontal | AODG | III | IDH mutant | 2018: Gross Total excision | 2018: EBRT 60 Gy in 30 cycles#, with concurrent TMZ | 10 | 13 |
43 | 36/F | Left frontoparietal | GBM | IV | IDH mutant | 2009: Gross Total excision 2016: Recurrence- re-exploration subtotal excision | 2009: EBRT60 Gy in 30 cycles#, with concurrent TMZ 2016: EBRT alone with no chemotherapy 2017: Bevacizumab | 24 | 13 |
44 | 34/M | Right temporoparietal | AODG | III | IDH mutant | 2018: Near total excision 2019: Re exploration subtotal excision | 2018: 60 Gy in 30 cycles#, with concurrent TMZ | 2 | 14 |
45 | 69/F | Right temporal | GBM | IV | IDH wildtype | 2019: Gross total excision | 2019: 60 Gy in 30 cycles#, with concurrent TMZ | 6 | 1 |
46 | 51/M | Left temporal | AODG | III | IDH wildtype | 2019: Gross total excision | 2019: 60 Gy in 30 cycles#, with concurrent TMZ | 3 | 13 |
47 | 50/M | Left parietal | GBM | IV | IDH wildtype | 2018: Gross total excision | 2018: EBRT RT 60 Gy in 30 cycles#, lost to follow-up | 12 | 12 |
48 | 43/F | Right parietal | AODG | III | NA | 2017: Gross total excision | 2018: EBRT RT 60 Gy in 30 cycles#, lost to follow-up | 78 | 7 |